Dabigatran Etexilate Mesylate

CAS 872728-81-9

General Information

Dabigatran Etexilate Mesylate is an orally available mesylate salt form of the etexilate prodrug of dabigatran, a benzimidazole and direct thrombin inhibitor with anticoagulant activity.

Upon administration, dabigatran etexilate is hydrolyzed by esterases and is converted into dabigatran. Dabigatran reversibly binds to and inhibits the activity of thrombin, a serine protease that converts fibrinogen into fibrin. This disrupts the coagulation cascade and inhibits the formation of blood clots. It is used to treat and prevent blood clots and to prevent stroke in people with atrial fibrillation. It is indicated to prevent blood clots following hip or knee replacement and in patients with a history of prior clots.

About the API

Technology Synthetic Organic Chemistry
Molecular Formula C34H41N7O5
Molecular Weight 627.734 g/mol
Therapeutic category Coagulation Inhibitors
Available formulations Oral Solid
Regulations EU DMF Flag EU DMF Korea DMF Flag Korea DMF US DMF Flag US DMF